A Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain

Phase 3 Completed 42 enrolled Lindner Center of HOPE Eli Lilly and Company · collab University of Cincinnati · collab

RandomizedParallel-groupQuadruple-blindPrevention

Summary

The specific aim of this study is to evaluate the efficacy, tolerability, and safety of zonisamide therapy in the prevention of weight gain associated with olanzapine treatment for psychotic or bipolar disorders.

Timeline

Start: 2008-01
Primary completion: 2011-02
Completion: 2011-02

Publications

Results McElroy SL, Winstanley E, Mori N, Martens B, McCoy J, Moeller D, Guerdjikova AI, Keck PE Jr. A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain. J Clin Psychopharmacol. 2012 Apr;32(2):165-72. doi: 10.1097/JCP.0b013e3182488758.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Zonisamide	Other / unclassified	100 mg	—
Subject	Zonisamide	Other / unclassified	600 mg	—
Background	Olanzapine	Small molecule	5 mg	—
Background	Olanzapine	Small molecule	20 mg	—

Indications

No indication recorded.